Compare TCOM & EW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TCOM | EW |
|---|---|---|
| Founded | 1999 | 1958 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Industrial Specialties |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 47.4B | 49.5B |
| IPO Year | 2003 | 2000 |
| Metric | TCOM | EW |
|---|---|---|
| Price | $75.67 | $85.23 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 20 |
| Target Price | $80.00 | ★ $96.11 |
| AVG Volume (30 Days) | 1.3M | ★ 3.0M |
| Earning Date | 02-23-2026 | 02-10-2026 |
| Dividend Yield | ★ 0.39% | N/A |
| EPS Growth | ★ 86.40 | N/A |
| EPS | ★ 6.25 | 2.33 |
| Revenue | ★ $8,393,499,281.00 | $5,883,800,000.00 |
| Revenue This Year | $18.23 | $14.29 |
| Revenue Next Year | $13.78 | $9.68 |
| P/E Ratio | ★ $12.29 | $36.30 |
| Revenue Growth | ★ 17.45 | 10.60 |
| 52 Week Low | $51.35 | $65.94 |
| 52 Week High | $78.65 | $87.89 |
| Indicator | TCOM | EW |
|---|---|---|
| Relative Strength Index (RSI) | 63.94 | 51.58 |
| Support Level | $75.75 | $83.93 |
| Resistance Level | $77.65 | $86.60 |
| Average True Range (ATR) | 1.07 | 1.38 |
| MACD | 0.43 | -0.19 |
| Stochastic Oscillator | 71.86 | 44.58 |
Trip.com is the largest online travel agent in China and is positioned to benefit from the country's rising demand for higher-margin outbound travel as passport penetration is only 12% in China. The company generated about 79% of sales from accommodation reservations and transportation ticketing in 2024. The rest of revenue comes from package tours and corporate travel. Before the pandemic in 2019, the company generated 25% of revenue from international travel, which is important to its margin expansion. Most of sales come from its domestic platform, but the company is expanding its overseas business. The competes in a crowded OTA industry in China, including Meituan, Alibaba-backed Fliggy, Tongcheng, and Qunar. The company was founded in 1999 and listed on the Nasdaq in December 2003.
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.